Quantcast

Latest TroVax Stories

2014-06-30 13:06:13

European Society for Medical Oncology ESMO 16 World GI Congress on Gastrointestinal Cancer The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. "Around 50% of patients with colorectal cancer develop metastases but eventually many of them do not respond to standard therapies,"...

2014-06-15 08:20:51

LONDON, June 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Hormone Refractory Breast Cancer Global Clinical Trials Review, H1, 2014http://www.reportbuyer.com/pharma_healthcare/drug_discovery/hormone_refractory_breast_cancer_global_clinical_trials_review_h1_2014.htmlHormone Refractory Breast Cancer Global Clinical Trials Review, H1, 2014 SummaryGlobalData's clinical trial report, "Hormone Refractory Breast Cancer Global Clinical Trials...

2014-05-06 23:01:41

Retrospective Study of Roswell Park Patients Documents Safety and Benefit of Complex Immunotherapy Buffalo, NY (PRWEB) May 06, 2014 A retrospective study published online ahead of print in the medical journal Urology by a physician team from Roswell Park Cancer Institute (RPCI) found that patients with metastatic kidney cancer — even those with chronic renal insufficiency — can tolerate and benefit from a treatment called high-dose interleukin-2 (HDIL-2) immunotherapy. Patients with...

2014-05-05 20:23:52

LONDON, May 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014http://www.reportbuyer.com/pharma_healthcare/research_rd/clinical_trials/renal_cell_carcinoma_global_clinical_trials_review.htmlRenal Cell Carcinoma Global Clinical Trials Review, H1, 2014SummaryGlobalData's clinical trial report, "Renal Cell Carcinoma Global Clinical Trials Review, H1, 2014" provides data on the Renal Cell Carcinoma...

2014-04-23 08:31:00

Third Phase 3 Trial of Custirsen to Receive FDA Fast Track Designation BOTHELL, Wash. and VANCOUVER, British Columbia, April 23, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of custirsen when administered in combination with cabazitaxel/prednisone for the treatment of men with metastatic castrate-resistant prostate cancer (CRPC) following...

2014-02-27 16:28:16

ThermoDox Demonstrates Impressive Response Rate in Refractory Patients LAWRENCEVILLE, N.J., Feb. 27, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in Recurrent Chest Wall Breast Cancer (RCWBC). The trial will enroll 20 patients at 5 clinical sites in the United States and is evaluating ThermoDox in combination with mild hyperthermia. Based on data available to date, a...

2014-02-12 12:30:03

WORCESTER, Mass. and TORONTO, Feb. 12, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (GNBT) today announced that recent results from a Phase II study of a novel cancer vaccine designed to prevent relapse in patients who have had breast cancer corroborate prior results from an interim analysis conducted in October of 2011. The Company plans to disclose full results from the Phase II clinical trial at this year's American Society of Clinical Oncology (ASCO)...

2014-01-30 12:28:09

AUSTIN, Texas, Jan. 30, 2014 /PRNewswire/ -- XBiotech announced today that its collaboration with the European Medicines Agency (EMA) has resulted in establishment of a regulatory path for Xilonix(TM) registration in the European Union for the treatment of colorectal cancer. XBiotech AG will soon launch its Phase III registration study in Europe to evaluate Xilonix in patients with treatment-resistant colorectal cancer. Cancer treatment centers in at least 6 countries will be involved...

2014-01-27 08:27:50

Latest Data from Large Subgroup of Patients Shows that the Combination of ThermoDox® and Optimized RFA Provides a Statistically Significant Survival Improvement of Over 50% LAWRENCEVILLE, N.J., Jan. 27, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced that the latest overall survival data from its post-hoc analysis of results from the Company's Phase III HEAT Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related